cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kota yogyakarta,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Cancer Chemoprevention
Published by Indonesian Society for Cancer Chemoprevention
ISSN : 23558989     EISSN : 20880197     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology
Indonesian Journal of Cancer Chemoprevention (IJCC) is an open access, peer-reviewed, triannual journal devoted to publishing articles on Cancer Chemoprevention including Experimental and Clinical Pharmacology, especially concerning Anti-Oxidants, Anti-Aging, Anti-Inflammation, Anti-Angiogenesis, and Anti-Carcinogenesis; Cancer Detection; Stem Cell Biology; Immunology; in vitro and in silico Exploration of Chemopreventive Mechanism; and Natural Products.
Arjuna Subject : -
Articles 7 Documents
 1 
Search results for , issue "Vol 14, No 1 (2023)" : 7 Documents clear
Bioinformatics Analysis of Inhibition Activation SHP-2 by Galangal as Activating Agent of Cancer Immunotherapy Ardriyanto, Maria Indra; Rahman, Faaza Aulia; Hastuti, Hanaan Emilia Adi; Meiyanto, Edy; Kawai, Taro; Putri, Dyaningtyas Dewi Pamungkas
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp1-11

Abstract

Interleukin 12 (IL-12) is a pro-inflammatory cytokine type 1 that has acted as a potential immunotherapy for cancer. The mechanism of IL-12 increases the activity of cytotoxic T cells and Natural Killer (NK) cells, reverse tumor-induced immunosuppression, prevent angiogenesis, and increases lymphocyte and antigen transport. Galangal is one of the natural ingredients that have biological activity as an anticancer and immunomodulator. In this research, researchers wanted to know the potential of the active compound of galangal to activate IL-12 by inhibiting the IL-12 analog, namely SHP-2. This research uses bioinformatics studies using several databases such as RCSB PDB, ChEMBL, Dr. Duke's Phytochemical and Ethnobotanical, UALCAN, OncoLnc and computational analysis using KNIME and MOE software. The SHP-2 structure used is taken from the RCSB PDB with the code 5EHR. The 10 compounds with the highest predictions of inhibiting SHP2 using KNIME were obtained, then molecular docking was performed using MOE and three compounds that had the potential to inhibit SHP-2 were Kaempferide, Galangin, and RiboflavinKeywords: cancer, computing, galangal, Interleukin 12, SHP-2.
Activity of Ethanol Fraction Melinjo (Gnetum Gnemon L.) Seed on Colonic Cancer (Widr) Cells as Co-Chemotherapy Agent Arifin, Nuha Haifa; Febriansah, Rifki; Octavia, Melany Ayu; Kenyori, Ivana Kinanti
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp49-59

Abstract

Cancer deaths increase every year, including in Indonesia. The low selectivity of chemotherapy agents and the resistance of cancer cells against chemotherapy agents is the main cause of chemotherapy treatment failure. It causes serious side effects in sufferers. Beside that, plants produce secondary metabolites which are being investigated for the anticancer activity that is used as new clinical drugs. Therefore we need research that uses plants as co-chemotherapy agents. Melinjo seeds (Gnetum gnemon L.) contain gnetin C has the potential to apoptosis WiDr colon cancer cells. The purpose of this study was to determine the potential of Ethanol Fraction Melinjo Seed (EFMS) as a co-chemotherapy agent for colon cancer. The sample was maceration using 70% ethanol and fractionated with ethanol. Phytochemical screening with thin layer chromatography (TLC)-Densitometry, antioxidant test used the DPPH, while the cytotoxic activity of WiDr colon cancer cells and their combination with 5-Fluorouracil chemotherapy agent using the 3-(4,-5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay, and also in silico test used molecular docking between gnetin C on EFMS and IKK and COX-2 proteins with the 5-FU. The results showed that EFMS contains gnetin C based on Rf value, has weak antioxidant activity with IC50 1227 μg/mL, weak cytotoxic activity in WiDr colon cancer cells with IC50 681 μg/mL and has combined activity synergistic with 5-Fluorouracil. Molecular docking showed gnetin C strong binding affinity against IKK and COX-2 proteins with scores -12.2 kcal/mol and -9.6 kcal/mol. The result concludes that EFMS has the potential to inhibit the development of cancer cells, especially WiDr colon cancer cells.Keywords: Gnetum gnemon L., Colon Cancer, Cytotoxic, Molecular docking, WiDr.
Correlation between Plasma Soluble CD36 Levels with Body Mass Index of Breast Cancer Patients in the Indonesian Population Rachman, Andhika; Irawan, Cosphiadi; R.R., Aditia; Koesnoe, Sukamto; Wijaya, Indra
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp12-21

Abstract

The cluster of differentiation 36 (CD36) is a multiligand receptor protein that plays a role in lipid metabolism. Its biological functions involve lipid uptake, immune recognition, inflammation, molecular adhesion, and tumor metastasis. Soluble CD36 (sCD36) is the circulating form of CD36 in plasma. Research on the role of sCD36 in breast cancer is limited. This study aimed to investigate sCD36 concentration and evaluate the correlation between sCD36 concentration and BMI in breast cancer patients. This is a multi-center cross-sectional study done from June 2018 to February 2019 in Indonesia. Consecutive sampling was done for women with invasive breast cancer aged 18-70. Patients with locoregional recurrences, multiple comorbidities, diabetes, stroke, or liver impairment were excluded. Patients were grouped based on their BMI into normo-weight and overweight/obese. Plasma sCD36 was analyzed using Bioassay Laboratory™ ELISA. The correlation between plasma sCD36 and the patient's characteristics (metastasis status and molecular subtype) were then analyzed. A total of 76 patients were enrolled, 36 of whom were categorized into the overweight/obese group and 40 of them in the normo-weight. Plasma levels of sCD36 in breast cancer patients were higher than controls at 0.24±0.163 ng/mL and 0.46±0.175 ng/mL, respectively (p=0.006). However, no difference in plasma sCD36 levels was found between the overweight/obese group and the normo-weight breast cancer subjects (p>0.05). Plasma sCD36 increased significantly in breast cancer patients, but no significant difference was found based on body mass index. Further research is needed to determine the role of sCD36 in determining clinical outcomes and prognosis in breast cancer patients.Keywords: Soluble CD36, body mass index, breast cancer, indonesia.
Bioinformatic Study of the Active Compound of Morusin in Mulberry (Morus alba) against Breast Cancer Sarmoko Sarmoko; Afif Hariawan Pratama; Nur Amalia Choironi; Muhammad Salman Fareza
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp60-71

Abstract

Morusin, an active constituent of the mulberry plant (Morus alba), exhibits inhibitory effects on several types of cancer cells in vitro, including breast cancer. This study aimed to identify potential target proteins of morusin, investigate the binding energy, and explore type of interactions between morusin and the target protein. Morusin target was searched using the PubMed, STITCH, STRING, and Cytoscape databases. Subsequently, the obtained morusin target protein data underwent processing using Autodock Tools and DS BIOVIA to facilate the simulation of molecular docking between morusin and the target protein. The study identified EGFR, SRC, and MAPK1 as potential targets for morusin. Docking simulations revealed that both EGFR and SRC represent viable targets for morusin, as their binding energies were lower than those of the native ligand and lapatinib. Specifically, the bond energies at EGFR were -9.6, -7.5, and -9.2 kcal/mol for morusin, the native ligand, and lapatinib, respectively. Similarly, at SRC, the corresponding bond energies were -8.2, -6.4, and -5.3 kcal/mol. Morusin demonstrated binding interactions with Leu694, Val702, Leu820, Ala719, Leu768, and Lys721 at the active site of EGFR, and with Lys295 and Gly344 at the binding active sites of SRC. Consequently, morusin has the potential to suppress cancer cell growth by targeting EGFR and SRC.Keywords: cancer cells, EGFR and SRC as targets, molecular docking, morusin, mulberry plant.
Distribution and Viability of Peripheral Blood Mononuclear Cells from Imatinib-resistant Chronic Myeloid Leukemia Patients: an In Vitro Study Ramadhanti, Julia; Utami, Kharima Dwi; Bashari, Muhammad Hasan; Wijaya, Indra
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp22-32

Abstract

The incidence of Chronic Myeloid Leukemia (CML) in the world is approximately 1.5 cases per 100,000 individuals. The level of resistance to CML treatment, imatinib in Indonesia is relatively high compared to Europe. Culturing CML cells can be used as a model for the determination of pathogenesis of CML, drug efficacy testing, and drug resistance testing. Studies using CML patients’ cells to be cultured in vitro and the methods used are rarely varied. This study aims to examine the distribution and viability of peripheral blood mononuclear cells from imatinib-resistant CML patients, expected to be a reference for mononuclear cell cultures from CML patients. This study was conducted in June-August 2019 using quantitative descriptive methods. The sample was mononuclear cells isolated from peripheral blood of three imatinib-resistant CML patients at the Hemato-Oncology Polyclinic of Hasan Sadikin Hospital, each of which was cultured in vitro using RPMI 1640 for 28 days. Distribution were seen using Giemsa staining, while viability was calculated using trypan blue. Data is processed using Microsoft Excel 2013 and Graphpad. Cell viability decreased during culture. Cell distribution had a different development pattern. Blast cells, eosinophils and basophils had presentation of between 0-5%. The percentage of lymphocyte changed between 11-31%. The percentage of neutrophil changed between 16-41%. The percentage of immature cells decreased, whereas the percentage of monocyte increased. In conclusion, cell viability decreases during the culture. Distribution of cells similar to the initial condition lasted until the 7th day and in the final phase it was only dominated by monocytes.Keywords: myeloid leukemia, chronic, cell culture, in vitro, peripheral blood mononuclear cell, cell viability.
Cytotoxic and Anti-proliferative Effects of Ethanol Extract of Marine Sponge Stylissa carteri on Colon Cancer HCT-116 Cell Line Resti Gradia Dwiwina; Sarah Sabrina; Yuni Susanti Pratiwi; Putri Halleyana; Adrikni Rahman; Muhammad Hasan Bashari
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp33-38

Abstract

Colorectal cancer is one of the most diagnosed cancers in the world. KRAS mutations in colon cancer are being responsible for the progressiveness and resistance of the standard therapeutic available. Marine sponge is one the sources for chemotherapy. Stylissa carteri is a marine sponge that lives in Indonesia and its anti-cancer effects are starting to be explored nowadays. The purpose of this study was to determine the cytotoxicity and anti-proliferative effect of ethanol extract of Stylissa carteri against colon cancer cells with KRAS mutations HCT-116 cells. This was an in vitro study using colon cancer cell line HCT-116 which was tested by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and trypan blue assay. The trypan blue assay was performed on control and treated cells at 72 h. The MTT assay was performed on cells which were previously incubated with Stylissa carteri extract. Sponge Stylissa carteri was taken from Pramuka island, Taman Nasional Kepulauan Seribu, Jakarta. The IC50 of ethanol extract of Stylissa carteri is 5 μg/mL (R square 0.9550) in HCT-116 cells. The trypan blue assay showed doubling time of incubated cell for 48 h was 26.10 h for control and 39.69 h for treated cells, respectively. Ethanol extract of Stylissa carteri has cytotoxic and anti-proliferative effects in HCT-116 colon cancer cells with KRAS mutation.Keywords: Colon Cancer, HCT-116, KRAS Mutation, Marine Sponge, Stylissa carteri.
Bioinformatic and Molecular Docking Study of Zerumbone and Its Derivates against Colorectal Cancer Fauziyya, Riri; Auli, Winni Nur; Suprahman, Nisa Yulianti; Sarmoko, Sarmoko; Ashari, Arif; Alsadila, Kalista; Agustin, Lanita; Fazila, Safia; Zahra, Miralda; Pane, Esteria Christina; Sukrasno, Sukrasno
Indonesian Journal of Cancer Chemoprevention Vol 14, No 1 (2023)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev14iss1pp39-48

Abstract

The prevalence of colorectal cancer (CRC) is ranked third among all cancer types in both men and women, highlighting the urgency for drug exploration. Zerumbone and its derivatives have gained attention for their ability to inhibit angiogenesis, invasion, and metastasis and have been tested for their efficacy against various cancer cells. This study aimed to investigate the potential targets and mechanism of action of zerumbone derivatives in colon cancer invasion and migration. Bioinformatic analysis was conducted using STITCH and STRING to identify potential target genes, and molecular docking was used to search for anticancer candidates from 20 zerumbone derivatives. The results revealed that six proteins were targeted by zerumbone derivatives, including XIAPBIR3 (1TFT), AKT1 (3O96), JAK2 (6VGL), HASP90AA (2XJX), MDM2 (4MDN), and XIAPBIR2 (4KJU). Compound 4 was found to have a lower binding energy than zerumbone as well as AZD5363 (pan-Akt inhibitor) when interacting with the protein target AKT1. This makes it the most promising candidate among the zerumbone derivatives for treating colorectal cancer. Further development, such as the addition of an amine functional group, is expected to improve the potency of this molecule through the formation of hydrogen bonds and other interactions with lower bond energy.Keywords: Bioinformatic, molecular docking, zerumbone derivatives, colorectal cancer.

Page 1 of 1 | Total Record : 7

 1 

Filter by Year

2023 2023


Reset
Filter By Issues
All Issue Vol 15, No 3 (2024) Vol 15, No 2 (2024) Vol 15, No 1 (2024) Vol 14, No 3 (2023) Vol 14, No 2 (2023) Vol 14, No 1 (2023) Vol 13, No 3 (2022) Vol 13, No 2 (2022) Vol 13, No 1 (2022) Vol 12, No 3 (2021) Vol 12, No 2 (2021) Vol 12, No 1 (2021) Vol 11, No 3 (2020) Vol 11, No 2 (2020) Vol 11, No 1 (2020) Vol 10, No 3 (2019) Vol 10, No 2 (2019) Vol 10, No 1 (2019) Vol 9, No 3 (2018) Vol 9, No 2 (2018) Vol 9, No 1 (2018) Vol 8, No 3 (2017) Vol 8, No 2 (2017) Vol 8, No 1 (2017) Vol 7, No 3 (2016) Vol 7, No 2 (2016) Vol 7, No 1 (2016) Vol 6, No 3 (2015) Vol 6, No 2 (2015) Vol 6, No 1 (2015) Vol 4, No 1 (2013) Vol 3, No 3 (2012) Vol 3, No 3 (2012) Vol 3, No 2 (2012) Vol 3, No 2 (2012) Vol 3, No 1 (2012) Vol 3, No 1 (2012) Vol 2, No 3 (2011) Vol 2, No 3 (2011) Vol 2, No 2 (2011) Vol 2, No 2 (2011) Vol 2, No 1 (2011) Vol 2, No 1 (2011) Vol 1, No 2 (2010) Vol 1, No 2 (2010) Vol 1, No 1 (2010) Vol 1, No 1 (2010) More Issue